PubMed · 7997038
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
R Butterworth, P Bath. Stroke scoring systems.. https://pubmed.ncbi.nlm.nih.gov/7997038/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Statins lower low-density lipoprotein cholesterol and are widely used for the prevention of atherosclerotic cardiovascular disease. Whether statin-induced low-density lipoprotein reduction increases risk of intracerebral haemorrhage has been debated for almost two decades. Here, we explored whether genetically predicted on-statin low-density lipoprotein response is associated with intracerebral haemorrhage risk using Mendelian randomization. Using genomic data from randomized trials, we derived a polygenic score from 35 single nucleotide polymorphisms of on-statin low-density lipoprotein response and tested it in the population-based UK Biobank. We extracted statin drug and dose information from primary care data on a subset of 225 195 UK Biobank participants covering a period of 29 years. We validated the effects of the genetic score on longitudinal low-density lipoprotein measurements with generalized mixed models and explored associations with incident intracerebral haemorrhage using Cox regression analysis. Statins were prescribed at least once to 75 973 (31%) of the study participants (mean 57 years, 55% females). Among statin users, mean low-density lipoprotein decreased by 3.45 mg/dl per year [95% confidence interval (CI): (-3.47, -3.42)] over follow-up. A higher genetic score of statin response [1 standard deviation (SD) increment] was associated with significant additional reductions in low-density lipoprotein levels [-0.05 mg/dl per year, (-0.07, -0.02)], showed concordant lipidomic effects on other lipid traits as statin use and was associated with a lower risk for incident myocardial infarction [hazard ratio per SD increment 0.98 95% CI (0.96, 0.99)] and peripheral artery disease [hazard ratio per SD increment 0.93 95% CI (0.87, 0.99)]. Over a 11-year follow-up period, a higher genetically predicted statin response among statin users was associated with higher intracerebral haemorrhage risk in a model adjusting for statin dose [hazard ratio per SD increment 1.16, 95% CI (1.05, 1.28)]. On the contrary, there was no association with intracerebral haemorrhage risk among statin non-users (P = 0.89). These results provide further support for the hypothesis that statin-induced low-density lipoprotein reduction may be causally associated with intracerebral haemorrhage risk. While the net benefit of statins for preventing vascular disease is well-established, these results provide insights about the personalized response to statin intake and the role of pharmacological low-density lipoprotein lowering in the pathogenesis of intracerebral haemorrhage.
LVV-hemorphin-7 is a peptide with opioid-like activity which is recognized by mu and sigma receptors. The sequence, derived from beta-, gamma-, delta- or epsilon- chains of human hemoglobin has been found in cerebrospinal fluid (CSF) of patients suffering from cerebrovascular bleedings, but not in CSF from healthy individuals. Procedures for isolation and identification of neuropeptides in body fluids and tissue extracts are often laborious and time-consuming. Additionally, extraction yield tends to be low after several chromatographic steps. In this study, we developed a rapid technique to analyze LVV-hemorphin-7 in CSF fluid from a patient with cerebrovascular bleedings using a combination of size-exclusion chromatography and electrospray ionization mass spectrometry. The methodology described utilizes small quantities of CSF (0.3-0.5 ml) and can be completed within a few hours. The proposed strategy opens possibilities for direct measurement of endogenous peptides in small volumes of body fluids.
Explore the source record for details and available documents.